Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Advertisement
Jordana JampelAdvanced Renal Cell Carcinoma | September 10, 2024
PFS was improved with nivolumab plus cabozantinib.
Read More
Katy MarshallAdvanced Renal Cell Carcinoma | September 6, 2024
A lack of research persists on the duration of therapy as well as the safety and efficacy of reinduction at progression.
Katy MarshallAdvanced Renal Cell Carcinoma | August 28, 2024
The hypoxia-inducible factor 2α inhibitor, belzutifan, has shown clinical activity in patients with ccRCC.
Katy Beckermann, MD, PhDAdvanced Renal Cell Carcinoma | September 4, 2024
In anticipation of ESMO, Dr. Katy Beckermann previews various clinical trials and studies to be presented in kidney cancer.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | August 12, 2024
Dr. Braun shares insights on updates to the NCCN guidelines for RCC, highlighting how they could impact clinical practice.
Katy MarshallAdvanced Renal Cell Carcinoma | August 5, 2024
Patients who received nivolumab plus ipilimumab experienced increased complete response rates compared with sunitinib.
Katy MarshallAdvanced Renal Cell Carcinoma | July 31, 2024
Researchers stated that the novel data source has the potential to inform patient care.
Katy MarshallAdvanced Renal Cell Carcinoma | July 23, 2024
The primary end point was ORR according to Immune Response Evaluation Criteria in Solid Tumors at 4 months.
Katy MarshallAdvanced Renal Cell Carcinoma | June 27, 2024
Bempegaldesleukin can initialize effector CD8+ T cells and natural killer cells in the tumor microenvironment.
Karine Tawagi, MDAdvancements in Oncology | June 12, 2024
Dr. Tawagi considers how "favorable" and "very favorable" risk alters her approach to patient management for aRCC.
Tian Zhang, MDAdvanced Renal Cell Carcinoma | July 8, 2024
Dr. Zhang highlights the results of a phase 2 trial for sequential treatment of cabozantinib in advanced RCC.
GU Oncology Now EditorsAdvancements in Oncology | June 6, 2024
The discussion focused on advanced and metastatic stages of RCC, shedding light on current practices in clinics.
Manmeet Ahluwalia, MD, MBA, FASCOAdvanced Renal Cell Carcinoma | June 10, 2024
The combination of SRS with IO significantly increases the OS in RCCBM compared with IO, WBRT, or WBRT plus IO.
Brandon TwyfordAdvanced Renal Cell Carcinoma | June 10, 2024
The KEYNOTE-426 study explored pembrolizumab and axitinib vs sunitinib in advanced RCC using genetic biomarkers.
Karl Semaan, MDAdvanced Renal Cell Carcinoma | June 5, 2024
Drs. Semaan and El Zarif detail an investigation into first-line systemic therapy following adjuvant immunotherapy for RCC.
Viktor Grünwald, MD, PhDAdvanced Renal Cell Carcinoma | August 19, 2024
Dr. Grünwald showcases patterns of progression and subsequent therapy for patients receiving len/pembro for aRCC.
Emily MenendezAdvanced Renal Cell Carcinoma | June 10, 2024
The trial previously demonstrated longer PFS rates with avelumab plus axitinib in patients with PD-L1-positive tumors.
Emily MenendezAdvanced Renal Cell Carcinoma | June 10, 2024
Patients who received lenvatinib plus pembrolizumab experienced later progression across tumors in multiple organs.
Zachary BessetteAdvanced Renal Cell Carcinoma | June 10, 2024
Patients with RCC who experience disease recurrence after adjuvant IO benefit from subsequent systemic therapies.
Katy MarshallAdvanced Renal Cell Carcinoma | June 7, 2024
Investigators found that the median follow-up period was 16.5 months at the study’s cutoff date.
Advertisement
Advertisement
Advertisement